XENE
Xenon Pharmaceuticals Inc. · Healthcare · Market cap $3.6B
Insiders bought $615K net in the last 90 days ·2 sellers, 2 buyers· 1 of 2 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 1, 2026
Insider Buying
$1.7M
reported purchases (SEC code P)
Insider Selling
$22.0M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Oct 17, 2026
Kelly Thomas Patrick
Xenon Pharmaceuticals Inc. (XENE) has 25 SEC Form 4 filings (51 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Oct 17, 2026.
Inside the rolling window, 7 insiders at Xenon Pharmaceuticals Inc. reported 2 open-market purchases totaling $1.7M and 15 open-market sales totaling $22.0M. The most active filer is PRESIDENT & CEO MORTIMER IAN with 8 filings. Insiders have net bought $481K over the trailing 6 months. The largest single insider purchase in this window was $1.1M by PRESIDENT & CEO MORTIMER IAN on Sep 30, 2026. The most recent open-market filing is a purchase of 15,000 shares by Chief Financial Officer Kelly Thomas Patrick, dated Sep 30, 2026, worth $560K.
- Industry:Biotechnology
- CEO:Ian C. Mortimer
- Employees:364
- HQ:Burnaby, BC, CA
- IPO:2014-11-05
| Source | |||||||
|---|---|---|---|---|---|---|---|
Kelly Thomas PatrickFirst filing | Chief Financial Officer | Purchase | 15,000 | $560K | Oct 1 | -3.6% | SEC ↗ |
MORTIMER IANFirst in 7 months | PRESIDENT & CEO | Purchase | 30,000 | $1.1M | Oct 1 | -3.6% | SEC ↗ |
KENNEY CHRISTOPHER JOHNFirst in 6 months | Chief Medical Officer | Sale | 7,068 | $426K | Sep 1 | -37.4% | SEC ↗ |
GANNON STEVENFirst filing | Director | Sale | 10,000 | $641K | Aug 13 | -41.6% | SEC ↗ |
PATOU GARYFirst filing | Director | Sale | 1,322 | $70K | Jun 8 | -26.7% | SEC ↗ |
Cannon GillianFirst filing | Director | Sale | 1,190 | $63K | Jun 8 | -26.7% | SEC ↗ |
| Chief Medical Officer | Sale | 1,410 | $78K | Mar 13 | -32.0% | SEC ↗ | |
| Chief Legal Officer | Sale | 1,342 | $74K | Mar 13 | -32.0% | SEC ↗ | |
| PRESIDENT & CEO | Sale | 7,308 | $404K | Mar 13 | -32.0% | SEC ↗ | |
| PRESIDENT & CEO | Sale | 270,000 | $16.3M | Mar 11 | — | SEC ↗ | |
| PRESIDENT & CEO | Sale | 11,269 | $677K | Mar 11 | — | SEC ↗ | |
KENNEY CHRISTOPHER JOHNFirst filing | Chief Medical Officer | Sale | 2,771 | $167K | Mar 11 | — | SEC ↗ |
DiFabio AndreaFirst filing | Chief Legal Officer | Sale | 2,607 | $157K | Mar 11 | — | SEC ↗ |
| PRESIDENT & CEO | Sale | 40,000 | $1.8M | Jan 2 | — | SEC ↗ | |
| PRESIDENT & CEO | Sale | 14,375 | $647K | Dec 9 | — | SEC ↗ | |
| PRESIDENT & CEO | Sale | 10,830 | $495K | Dec 9 | — | SEC ↗ | |
MORTIMER IANFirst filing | PRESIDENT & CEO | Sale | 97 | $4K | Dec 3 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does XENE have?
Xenon Pharmaceuticals Inc. (XENE) has 25 SEC Form 4 filings (51 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Oct 17, 2026.
When was the most recent SEC Form 4 filing for XENE?
The most recent Form 4 filing for XENE on Tracefour is dated Oct 17, 2026.
Who is the most active insider at XENE?
The most active SEC Form 4 filer at XENE in the rolling window is PRESIDENT & CEO MORTIMER IAN, with 8 filings.
What is the net insider flow at XENE over the last 6 months?
Over the trailing 180 days, insiders at XENE have net bought $481K based on SEC Form 4 disclosures.
What was the largest insider purchase at XENE?
The largest single insider open-market purchase at XENE in the rolling window was $1.1M by PRESIDENT & CEO MORTIMER IAN on 2026-09-30.
What is the total insider buy and sell value at XENE in the current window?
Inside the rolling window, insiders at XENE bought $1.7M and sold $22.0M based on SEC Form 4 filings.
Can I get alerts for XENE insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Xenon Pharmaceuticals Inc. (XENE). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Xenon Pharmaceuticals Inc. is in the Healthcare sector.